Some neutralizing antibodies against SARS-CoV-2 may heighten lung tissue damage from COVID-19, an A*STAR study finds.
From forming protective physical barriers to stabilizing mRNA vaccines, polymers provide endless solutions to the threat of coronaviruses and other current and impending diseases.
In COVID-19 long-haulers, an unrelenting immune response damages blood vessels, making them more susceptible to developing blood clots.
The amount of neutralizing antibodies produced by COVID-19 patients—and the length of time they remain detectable—can vary wildly, a study suggests.
Understanding why COVID-19 tends to strike the old but spare the young could inform how to prioritize limited COVID-19 vaccines.
Four newly discovered SARS-CoV-2 peptides not only promise to make COVID-19 tests cheaper and more specific, but may also reveal disease severity.
In a classic case of double trouble, the binding of SARS-CoV-2’s spike protein to bacterial lipopolysaccharide supercharges inflammation in COVID-19 patients.
These novel immune signatures identify patients most at risk for developing severe COVID-19 symptoms.
Lockdown measures not only reduced the number of COVID-19 cases but also resulted in a temporary improvement in air quality, study finds.
Using flow cytometry, researchers have developed a sensitive and specific test for COVID-19 that can identify asymptomatic carriers.
Plant-based ionizers are surprisingly effective at removing aerosols and could play an important role in preventing COVID-19 transmission.
A multifaceted study by the Singapore 2019 Novel Coronavirus Outbreak Research team is filling in some of the gaps left in the urgent quest to understand COVID-19 infection.